Reata Pharmaceuticals, which is developing therapies for life-threatening forms of pulmonary hypertension, raised $60.5 million by offering 5.5 million shares at $11. It had originally planned to raise $60 million by offering 4.0 million shares at a range of $14 to $16. Reata Pharmaceuticals plans to list on the Nasdaq under the symbol RETA. Citi, Cowen & Company and Piper Jaffray acted as lead managers on the deal.
